Cipla is looking at continued growth across all its key markets in the current fiscal year (FY20) and plans to file over 12 abbreviated new drug applications during the period. For the Indian market, it is looking at strong growth in existing franchises including respiratory and ramp-up of chronic therapies such as diabetes, cardio and women health.
For the US market, where the company has seen significant growth driven by ramp-up across key differentiated products in FY19, it is looking to scale-up last fiscal's launches and also introduce more products in FY20 while continuing the specialty investments.
In another key market of South Africa, during the current fiscal year Cipla is looking to strengthen its OTC (over-the-counter) business. In the rest of world market, the company will be focusing on continuing market leadership in key regions.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1532.85 |
Dr. Reddys Lab | 5812.50 |
Cipla | 1403.90 |
Zydus Lifesciences | 1104.45 |
Lupin | 1661.90 |
View more.. |